Mijatovic Tatjana, Jungwirth Ute, Heffeter Petra, Hoda Mir Ali Reza, Dornetshuber Rita, Kiss Robert, Berger Walter
Unibioscreen SA, Brussels, Belgium.
Cancer Lett. 2009 Sep 8;282(1):30-4. doi: 10.1016/j.canlet.2009.02.048. Epub 2009 Mar 31.
We recently reported that over-expressed Na(+)/K(+)-ATPase alpha subunits are new important anti-cancer targets. Cardiotonic steroids are the natural ligands of Na(+)/K(+)-ATPase and thus potentially potent anti-cancer agents with a novel mechanism of action. We report here that the hemi-synthetic cardenolide 19-hydroxy-2''oxovoruscharin is impressively active in cancer cells expressing diverse forms of multi-drug resistance (MDR) either conferred by the over-expression of selected drug-transporter proteins or induced by a range of chemotherapeutic agents. Together with the inability of tumor cells to acquire resistance to 19-hydroxy-2''oxovoruscharin, our data suggest that this novel compound could be especially applicable to notoriously drug-resistant cancers.
我们最近报道,过表达的Na(+)/K(+)-ATP酶α亚基是新的重要抗癌靶点。强心甾类是Na(+)/K(+)-ATP酶的天然配体,因此可能是具有新作用机制的强效抗癌剂。我们在此报告,半合成强心甾内酯19-羟基-2''氧代伏牛花素在表达多种形式多药耐药性(MDR)的癌细胞中具有显著活性,这些耐药性要么由特定药物转运蛋白的过表达引起,要么由一系列化疗药物诱导。连同肿瘤细胞无法对19-羟基-2''氧代伏牛花素产生耐药性,我们的数据表明,这种新型化合物可能特别适用于众所周知的耐药癌症。